Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-25-145
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Health
- Education
- Eligible applicants
-
- County Governments
- For Profit Organizations
- Non-501(c)(3) Nonprofits
- Special District Governments
- Higher Education Inst. (Private)
- State Governments
- Independent School Districts
- City/Township Governments
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- Small Businesses
- Other
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Public)
- Tribal Organizations (Not Federally Recognized)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for research on Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) with an application due date of January 7, 2028.
Eligible applicants include higher education institutions (public and private), 501(c)(3) nonprofits, for-profit organizations, small businesses, state and local governments, tribal governments and organizations, county governments, city and township governments, special district governments, independent school districts, public or Indian housing authorities, and other organizations. Additional eligible applicants include HBCUs, Hispanic-serving institutions, Asian American Native American Pacific Islander Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, U.S. territories or possessions, and non-domestic entities.
The FOA funds basic, translational, and clinical research projects designed to identify mechanisms of therapy-induced adverse sequelae, clinically characterize adverse sequelae, or translate mechanistic understanding into therapeutic interventions to prevent or minimize long-term sequelae from cancer therapies. Research should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints including biomarkers, imaging, patient-reported outcomes, or combined elements for use in future clinical trials evaluating intervention efficacy.
Applications are evaluated on scientific merit and technical adequacy by scientific peer review panels and subject to review by the National Cancer Advisory Board. All competitive applications compete for available funds based on scientific and technical merit, program relevance, and program balance consistent with NCI and NIH priorities.
The funding opportunity is assigned CFDA 93.393 (Cancer Cause and Prevention Research).
Synopsis
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-145-Full-Announcement.html | HTML file | |
| PKG00288553.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity